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Abstract: MicroRNAs (miRNAs) are small molecules of single strand non-coding RNAs, 
which are able to regulate gene expression. miRNAs have been involved in multiple 
cellular processes, such as proliferation, apoptosis and differentiation, thus alterations in 
miRNA expression have been shown to be directly linked with the pathological origin of 
multiple diseases, including cancer. In this way, during last few years, an increasing 
number of exciting advances have contributed to the understanding of miRNA roles in 
cancer. Moreover, researchers have exploited the special characteristics of miRNAs, such 
as the tissue and disease specificity or miRNA presence in blood, to explore their use as 
non-invasive tumour markers. In the present review, we summarize the current data on the 
potential usefulness of circulating miRNAs as diagnostic and prognostic tools in 
gastrointestinal tumours. 
Keywords: circulating microRNAs; biomarkers; gastrointestinal cancer; oesophageal cancer; 
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1. Introduction 
Cancer is a major worldwide health issue and represents the second leading cause of death after 
cardiovascular diseases [1]. Among cancers, gastrointestinal (oesophageal, gastric, pancreatic, hepatic 
and colorectal) cancer is one of most diagnosed and, together with breast and lung tumours, is 
responsible for most deaths. Moreover, despite the intense efforts and advances in the understanding of 
the molecular causes of this disease, there is no definitive therapeutic solution. Current treatments have 
improved the curative expectations and the quality of life of patients; however, the effectiveness of 
these new tools depends largely on the stage in which tumours can be detected. Therefore, it is clearly 
needed to investigate potential biomarkers with capacity to detect malignancies at early stages and in a 
fast, simple, sensitive and specific way. While the detection of current cancer biomarkers is 
sufficiently fast and simple, unfortunately, their diagnostic and prognostic performance is poor, which 
hinders their clinical use [2]. Moreover, despite the large number of studies on circulating biomarkers 
for different tumours, few proposals have been translated into clinical practice. 
MicroRNAs (miRNAs), small (18–22 nucleotides) single-stranded RNA molecules with regulatory 
functions [3], have become the focus of most recent efforts in cancer research. The importance of 
miRNAs lies in their extensive regulatory capacity, since a single miRNA is able to control the 
expression of hundred of genes [4,5], contributing to the global coordination of complex cellular 
processes, such as the proliferative control of stem cells [6]. Given this premise, the alteration in 
miRNA expression is considered one of the molecular abnormalities behind cancer development. In 
addition, miRNA expression is tissue specific [7] and therefore, the alteration of specific miRNAs in 
different tissues can be associated with concrete tumours [8]. In fact, it is possible to classify a tumour 
sample of unknown nature, even a metastatic one, by the identification of the tissue on which the 
primary tumour has been generated [9]. These characteristics make of miRNAs, powerful tools for 
diagnostic and prognostic purposes, as well as attractive therapeutic targets in cancer (for review, see [10]). 
Moreover, miRNAs are detected in blood at multiple physiological and pathological states, including 
cancer [11]. Most importantly, miRNAs are protected from degradation by ribonucleases in blood [12], 
enabling their detection and their use as non-invasive biomarkers. In this review, we summarize  
the current knowledge about the diagnostic and prognostic applications of circulating miRNAs in 
gastrointestinal cancer. 
2. Sources of Circulating MiRNAs in Cancer  
The origin and function of circulating nucleic acids in cancer, including miRNAs, is still under 
discussion (for a review, see [13]). The existence of circulating miRNAs in healthy individuals per se [14] 
or associated to different physiological events, such as pregnancy [15], underlines that their roles are not 
restricted to cancer. Therefore, circulating miRNAs in cancer may derive from multiple sources, 
including not only apoptosis and necrosis of circulating and primary tumour cells, but also the active 
release carried out by immune cells and other blood cells. Although there are different theories, the 
precise function of these circulating miRNAs in cancer remains unclear. One possibility is that cancer 
cells liberate immunosuppressive miRNAs allowing the tumour to evade the immune response. Cancer 
cells may also release oncogenic miRNAs contributing to their uncontrolled proliferation, the 
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malignant transformation of surrounding cells and the recruitment of new blood vessels. Alternatively, 
immune cells may also produce miRNAs to stimulate the response against cancer cells while tumour 
surrounding cells may generate tumour-suppressive miRNAs to arrest the extension of malignancy  
(for review, see [16]).  
Stability is another additional and interesting characteristic of circulating miRNAs which makes 
possible their detection and analysis, and, therefore, opening the door to their use as molecular 
markers. Moreover, this feature suggests that miRNAs do not circulate free in the bloodstream but are 
released as part of lipid or protein complexes that prevent the action of blood ribonucleases. The nature 
of these macromolecular complexes is in close relation to the source of transported miRNAs. Thus, 
while living cells actively release miRNAs encapsulated in large lipoprotein complexes (exosomes or 
microvesicles), miRNAs from dead or dying cells can be found in blood associated to Argonaute2 
(Ago2) protein (for a review, see [10]). Since it has been hypothesised that most extracellular 
miRNAs, including plasma miRNAs, are part of Ago2 complexes, and given the increased amount of 
circulating miRNAs in cancer, it is possible speculate that these circulating miRNAs predominantly 
derive from apoptotic and necrotic processes occurring in tumour cells. Therefore, circulating miRNAs 
in cancer are a good reflection of the underlying disease, providing valuable tools to monitor the 
pathological changes during the clinical course of tumours. Taken together this premise and the 
miRNA tissue specificity, it can be proposed that circulating miRNAs are not only excellent 
biomarkers for cancer detection but also for prognostic purposes. 
3. Circulating MiRNAs as Biomarkers in Gastrointestinal Cancer 
In the last few years, studies on miRNAs as tumour markers have emerged as a field of special 
interest in gastrointestinal cancer according to the huge number of publications. However, while most 
studies are focused on the analysis of miRNA expression in tissue specimens, only a limited number of 
them have addressed the usefulness of circulating miRNAs as biomarkers in blood, serum or plasma 
samples. In this section, we will focus on the most relevant findings about the utility of circulating 
miRNAs as biomarkers in gastrointestinal cancer, i.e., oesophageal, gastric, pancreatic, hepatic and 
colorectal cancer.  
The first attempt to identify circulating miRNAs as biomarkers in oesophageal cancer (Table 1) was 
made by Zhang and co-workers in 2010 [17]. In this study, a set of seven miRNAs, including miR-10a, 
miR-22, miR-100, miR-148b, miR-223, miR-133a and miR-127-3p, was identified and validated as a 
diagnostic signature after analysing 290 serum samples from squamous cell carcinoma (SCC) patients. 
These seven miRNAs showed excellent diagnostic capacities in combination or as single markers, 
showing a great area under the Receiver Operating Characteristic (ROC) curves (AUCs). Although the 
AUC for the seven-miRNA signature was 0.929, the maximum value reached was for miR-22 serum 
determination (0.949) and the minimum value for miR-100 (0.817); both values are above the AUC 
(0.549) for the carcinoembryonic antigen (CEA), a conventional serum marker. In addition, the cluster 
analysis revealed the ability of seven-miRNA panel to discriminate between early stage patients and 
healthy subjects. In 2011, two additional reports focused on the diagnostic and prognostic roles of 
circulating miRNAs in oesophageal cancer were published simultaneously. The first one was focused on 
the analysis of miR-31 levels in serum from 201 SCC patients as a diagnostic and prognostic tool [18]. 
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While the diagnostic performance of miR-31 was high both in the training (AUC = 0.902) and 
validation (AUC = 0.888) datasets, the most relevant conclusion was the independent association of 
high serum levels for miR-31 with poor relapse-free survival (hazard ratio: 3.260; 95% confidence 
interval: 1.264–8.421; p-value = 0.015). In the second study [19], an assay that combines the 
determination of miR-375 and miR-21 levels (miR-21/miR-375 ratio) in plasma for SCC diagnostic 
was developed, reaching an AUC of 0.816.  
Table 1. Circulating miRNAs with diagnostic and prognostic applications in oesophageal cancer.  
1 Tumor, Node, Metastasis staging system; 2 Up-regulation or Down-regulation regarding control samples;  
3 References; 4 Quantitative reverse transcription polymerase chain reaction; 5 Squamous cell carcinoma;  
6 Unknown. 
Regarding gastric cancer (Table 2), an incipient study published by Tsujiura and co-workers [20] 
evaluated by qRT-PCR the usefulness as diagnostic markers of five miRNAs (miR-17-5p, miR-21, 
miR-106a, miR-106b and let-7a) in plasma from 69 patients and 30 healthy individuals. The analysis 
of individual ROC curves demonstrated that miR-106b had the best AUC (0.721), while the combined 
assay for miR-106a/let-7a ratio improved this AUC, reaching 0.879. Therefore, miR-106b expression 
and miR-106a/let-7a ratio were proposed as the first non-invasive plasma biomarkers for gastric cancer 
diagnosis. MiR-106a was also detected in blood from gastric cancer patients and it was proposed to be 
a potential biomarker for detecting circulating tumour cells [21]. On the other hand, miR-17 alone or in 
combination with miR-106a, showed superior diagnostic properties as show the AUCs obtained from 
ROC curve analysis (0.684 for miR-106a, 0.743 for miR-17, and 0.741 for the combination) [21]. 
More recent and extensive studies investigated, by genome-wide approaches, circulating miRNAs with 
potential diagnostic applications in gastric cancer [22–24]. In one of these studies, Solexa sequencing 
was performed to discover miRNAs differentially expressed in pooled serum samples from 20 
metastatic, 20 non-metastatic and 20 healthy donors. From this discovery stage, 22 miRNA candidates 
were selected and subsequently analysed by qRT-PCR in a training cohort of 22 gastric cancer cases 
and 22 controls. The five-miRNA signature (miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p) thus 
identified was further validated by analysing serum from 142 gastric cancer patients and 105 matched 
controls. Both in training and validation datasets, the five-miRNA panel reached excellent diagnostic 
miRNAs Samples (n) 
TNM 1 Stage 
(patients) 
Technique 
Up/ 
Down 2 
Association Ref. 3 
7-miRNA panel: 
miR-10a, miR-22, 
miR-100, miR-133a, 
miR-127-3p,  
miR-148b, miR-223 
Serum  
(290 patients, 
140 controls) 
0 (2), I (18), 
II (81),  
III (31),  
IV (11),  
X 6 (6) 
Deep-sequencing + 
qRT-PCR 4 
Up Diagnosis of SCC [17] 
miR-31 Serum  
(201 patients, 
202 controls) 
I (28), II (31), 
III (33),  
IV (28) 
qRT-PCR Up Poor relapse-free 
and tumour-specific 
survival/Diagnosis 
of SCC 
[18] 
miR-21/ 
miR-375 ratio 
Plasma  
(50 patients, 
20 controls) 
I-II (25),  
III-IV (25) 
qRT-PCR Up Diagnosis of SCC 5 [19] 
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properties with respective AUCs of 0.879 and 0.831, clearly superior to AUCs obtained for the CA19-9 
carbohydrate antigen and CEA (0.600 and 0.503, respectively) [22]. Other studies were performed using 
microarrays instead deep sequencing in the phase of biomarker discovery. Liu and co-workers [23] 
obtained seven miRNA candidates that were subsequently analysed by qRT-PCR in a training cohort 
of 30 gastric cancer patients and 30 healthy controls. Only three of them (miR-187*, miR-371-5p and 
miR-378) were selected for further validation in a cohort consisting of serum from 40 gastric cancer 
patients and 41 controls. The best AUC was obtained for miR-378 (0.861); in addition, a multivariate 
analysis, including the three candidate miRNAs, demonstrated that only miR-378 had diagnostic 
independence (odds ratio: 16.917; 95% confidence interval: 5.337–53.616; p-value < 0.0001) [23]. 
Microarrays were also used by Konishi and colleagues to identify miR-451 and miR-486 as plasma 
biomarkers for gastric cancer detection (respective AUCs: 0.96 and 0.92) [24]. However, Song and 
colleagues used qRT-PCR low-density arrays to identify miRNA biomarkers in serum of gastric cancer 
patients [25]. The panel of miRNAs obtained (miR-221, miR-376c, and miR-744) showed the best 
sensitivity (0.824) and specificity (0.588), using the cut-off values obtained from the analyses of ROC 
curves for each miRNA (AUCs: 0.70 for miR-221; 0.71 for miR-376c; and 0.74 for miR-744). 
Table 2. Circulating miRNAs with diagnostic and prognostic applications in gastric cancer.  
miRNAs Samples (n) TNM 1 Stage 
(patients) 
Technique Up/ 
Down 2 
Association Ref. 3
miR-106b Plasma  
(69 patients, 
30 controls) 
I (38), II (13),  
III (14), IV (4) 
qRT-PCR 4 Up Gastric cancer 
diagnosis 
[20] 
miR-106a/  
let-7a ratio 
Plasma  
(69 patients, 
30 controls) 
I (38), II (13),  
III (14), IV (4) 
qRT-PCR Up Gastric cancer 
diagnosis 
[20] 
miR-17, miR-106a Blood  
(90 patients, 
27 healthy 
controls) 
Not provided qRT-PCR Up Circulating 
tumour cell 
detection; 
gastric cancer 
diagnosis 
[21] 
5-miRNA signature: 
miR-1, miR-20a, 
miR-27a, miR-34, 
miR-423-5p 
Serum  
(164 patients, 
127 controls) 
I (29), II (56),  
III (48), IV (23), 
X 5 (8) 
Deep 
sequencing + 
qRT-PCR 
Up Gastric cancer 
diagnosis 
[22] 
miR-378 Serum  
(57 patients, 
61 controls) 
I (6), II (14),  
III (18), IV (19) 
Microarray + 
qRT-PCR 
Up Gastric cancer 
diagnosis 
[23] 
miR-451, miR-486 Plasma  
(56 patients, 
30 controls) 
I+II (33),  
III-IV (23) 
Microarray + 
qRT-PCR 
Up Gastric cancer 
diagnosis 
[24] 
miR-221, miR-376c, 
miR-744 
Serum  
(82 patients, 
82 controls) 
Not provided qRT-PCR 
array 
Up Gastric cancer 
diagnosis 
[25] 
miR-17-5p, miR-20a Plasma  
(87 patients) 
I+II (40), III (37), 
IV (10) 
qRT-PCR Up Poorer overall 
survival 
[26] 
1 Tumor, Node, Metastasis staging system; 2 Regarding control samples; 3 References; 4 Quantitative reverse 
transcription polymerase chain reaction; 5 Unknown. 
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Finally, a recent study analysed the correlation between plasma miRNA levels and prognostic 
variables in gastric cancer [26]. They demonstrated that patients with elevated levels of miR-17-5p and 
miR-20a in plasma showed lower overall survival (p-value = 0.003 for both miRNAs). Moreover, as 
indicated by multivariate analysis, increased plasma levels of miR-20a was an independent risk factor for 
shorter overall survival in these patients (hazard ratio: 1.576; 95% confidence interval: 1.102–2.253;  
p-value = 0.013). 
The first study on circulating miRNAs as biomarkers in pancreatic cancer patients was performed 
in 2009 by Wang and co-workers (Table 3) [27]. The authors analysed by qRT-PCR the expression 
of four miRNAs (miR-21, miR-210, miR-155 and miR-196a) in plasma from 49 pancreatic ductal 
adenocarcinoma (PDAC) patients and 36 healthy controls, achieving a good diagnostic performance 
for this miRNA panel. While the independent analysis of ROC curves for each miRNA gave rise to 
AUCs ranging from 0.62 (miR-21) to 0.69 (miR-196a), the combination of the entire panel improved 
the AUC (0.82) as well as the sensitivity (0.64) and specificity (0.89) at the optimal cut-point. In 
another posterior study, high levels of miR-196a in serum were associated with unresectable PDACs 
(AUC = 0.864) and shorter survival [28]. The same group analysed the expression of seven miRNAs 
(miR-16, miR-21, miR-155, miR-181a, miR-181b, miR-196a and miR-210) in plasma from 
pancreatic cancer patients, chronic pancreatitis patients and healthy individuals [29]. While the 
individual miRNAs reached good diagnostic properties, the combination of miR-16 and miR-196a 
provided the best results. The diagnostic capacity of this miRNA panel was further improved when  
it was combined with CA19-9 levels, increasing the AUC, specificity and sensitivity. Most 
importantly, the combinatory marker (miR-16 + miR-196a + CA19-9) showed an enhanced capacity 
for the detection of stage I pancreatic cancer compared to CA19-9 (respective detection rates: 85.2% 
and 55.6%). Two groups further explored the role of circulating miRNAs as diagnostic tools in 
pancreatic cancer. First, miR-18a was established as a powerful biomarker (AUC = 0.9369) for 
pancreatic cancer diagnostic in plasma [30]. Second, an extensive genome-wide analysis was 
performed by deep-sequencing in order to discover miRNAs with altered expression in serum from 
pancreatic cancer patients, followed by testing and validation of their potential diagnostic usefulness [31]. 
The analysis demonstrated the ability of a seven-miRNA signature (miR-20a, miR-21, miR-24,  
miR-25, miR-99a, miR-185, and miR-191) to discriminate pancreatic cancer from healthy controls  
(AUC = 0.992, p-value = 0.027 in training cohort; AUC = 0.985, p-value = 0.027 in validation cohort) 
and from chronic pancreatitis (AUC = 0.993; p-value = 0.008). More importantly, this seven-miRNA 
panel can be also used to detect pancreatic cancer cases at early stages (detection rates: 96.2% and 
91.7% of cases at stages I and II), clearly improving the detection rates of conventional serum 
markers CA19-9 (detection rates: 46.2% and 62.5% of cases at stages I and II) and CEA (detection 
rates: 30.8% and 31.3% of cases at stages I and II). In addition, elevated levels of miR-21 in serum 
were identified as an independent predictor of poor survival in pancreatic cancer patients (Hazard 
ratio: 8.77; 95% confidence interval: 2.00–38.39; p-value < 0.01). 
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Table 3. Circulating miRNAs with diagnostic and prognostic applications in pancreatic cancer.  
miRNAs Samples (n) 
Stage 
(patients) 
Technique 
Up/ 
Down 1 
Association Ref. 2 
4-miRNA 
signature: miR-21, 
miR-210, miR-155, 
miR-196a 
Plasma  
(49 patients,  
36 controls) 
Localized (15), 
locally 
advanced (13), 
metastatic (21) 
qRT-PCR 3 Up Diagnosis of 
pancreatic 
adenocarcinoma 
[27] 
miR-196a Serum  
(35 patients,  
15 pancreatitis, 
15 controls) 
TNM 4: IB (9), 
IIA (6), IIB (9), 
III (5), IV (6) 
qRT-PCR Up Un-resectability 
and short survival 
[28] 
2-miRNA 
signature: miR-16, 
miR-196a  
(±CA519-9) 
Plasma  
(138 tumours, 
107 pancreatitis, 
68 controls) 
TNM: I (27), 
II (39), III (17), 
IV (55) 
qRT-PCR Up Early diagnosis of 
pancreatic cancer; 
chronic pancreatitis 
diagnosis 
[29] 
miR-18a Plasma  
(36 patients,  
30 controls) 
TNM: Ib (1), 
IIa (7), IIb (13), 
IV (8) 
qRT-PCR Up Diagnosis of 
pancreatic cancer 
[30] 
7-miRNA panel: 
miR-20a, miR-21, 
miR-24, miR-25, 
miR-99a, miR-185, 
miR-191 
Serum  
(197 tumours, 
82 pancreatitis, 
158 healthy 
donors) 
TNM: I (26), 
II (48), III (45), 
IV (66),  
X 6 (12) 
Deep 
sequencing + 
qRT-PCR 
Up Early diagnosis of 
pancreatic cancer 
[31] 
miR-21 Serum  
(38 tumours) 
Not provided qRT-PCR Up Poor survival [31] 
1 Regarding control samples; 2 References; 3 Quantitative reverse transcription polymerase chain reaction;  
4 Tumor, Node, Metastasis staging system; 5 Carbohydrate antigen; 6 Unknown. 
Up to date, most studies on liver cancer have focused on the most prevalent subtype, the 
hepatocellular carcinoma (HCC), and its close relationship with hepatitis B virus (HBV) infection and 
cirrhosis. This is also extensible to studies on circulating miRNAs and biomarker discovery (Table 4). In 
2009, Yamamoto and co-workers reported the first work where significantly higher levels of miR-500 in 
serum of HCC patients were found, although diagnostic performance data were not provided [32]. Later 
on, for the first time, Gui and co-workers provided data on the diagnostic capacity of a circulating 
miRNA, miR-885-5p, in HCC. They obtained miR-885-5p from a global serum miRNA profiling 
using qRT-PCR low-density arrays. The AUC for the determination of miR-885-5p levels in serum 
was 0.904, which allowed to discriminate patients with different liver pathologies (HCC, chirrosis, and 
chronic hepatitis B) from healthy controls with a sensitivity of 90.53% and a specificity of 79.17% [33].  
A more comprehensive study was conducted by using deep-sequencing technology, achieving the 
identification of two miRNA signatures in serum that allow the diagnosis of hepatitis B/C infection and 
hepatitis B virus (HBV)-associated HCC [34]. The miRNA signature for HBV-associated HCC diagnosis 
was composed of miR-25, miR-375, and let-7f. These miRNAs were able to discriminate cases from 
healthy controls with excellent specificity and sensitivity (99.1% and 97.9%, respectively; AUC: 0.9967). 
Interestingly, a single component of the previous signature, miR-375, maintains exceptional diagnostic 
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parameters with a specificity of 96% and a sensitivity of 100%. In a similar way, two miRNAs, miR-10a 
and miR-125b, were capable to distinguish HBV-infected patients from HBV-associated HCC cases with a 
specificity and sensitivity of 98.5%, and an AUC of 0.992 [34]. A later work performed also on serum 
samples allowed the discovery of miR-21, miR-122 and miR-223 as excellent biomarkers for HCC 
(respective AUCs = 0.87, 0.79 and 0.86) and chronic hepatitis (respective AUCs = 0.91, 0.93 and 0.88) [35]. 
Moreover [36], on the basis of previous works, seven miRNAs (miR-1, miR-16, miR-122a, miR-139,  
miR-195, miR-199a, and miR-224) were evaluated in serum with the purpose to discriminate HCC from 
chronic liver diseases. Since miR-1, miR-122a, miR-139, and miR-224 were undetectable in serum, the 
diagnostic reliability for HCC detection was determined for the remaining miRNAs (miR-16, miR-199a, 
and miR-195). From these three miRNAs, only miR-16 and miR-199a showed capacity to separate patients 
with HCC from those with chronic liver disease. By using the cut-off values provided by the distribution 
curves of each miRNA, both miRNAs showed superior sensitivity than conventional serum markers (AFP: 
α-fetoprotein; AFP-L3: Lens culinaris agglutinin-reactive α-fetoprotein; DCP: des-γ-carboxyprothrombin) 
to separate HCC and chronic liver diseases. The best sensitivity (92.4%) and specificity (78.5%) was 
achieved by the combination of miR-16 with conventional serum markers. MiR-16 used in second-line 
testing, after conventional serum markers, was also able to detect HCC in 69.2% of initially negative 
cases. By a genome-wide exploratory approach, similar to the procedure used by Lee and co-workers in 
a previous work [34] but based on microarray analysis instead of deep sequencing, plasma miRNAs  
were recently identified as biomarkers for HBV-related HCC diagnosis [37]. Seven plasma miRNAs  
(miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801) were proposed as diagnostic 
signature with capacity to discriminate HBV-related HCC from healthy controls (specificity: 93.9%; 
sensitivity: 83.2%; AUC: 0.941) and hepatitis B (specificity: 79.1%; sensitivity: 76.4%; AUC: 0.842). 
Although he components of this miRNA panel do not match to any of the previously employed by Li 
and co-workers [34], in other studies [35], however, they have used several of these miRNAs. This is 
the case of miR-122, which was again identified as serum biomarker to distinguish HBV-related HCC 
patients from healthy controls (AUC = 0.869) in the Chinese population [38]. Finally, only one study 
assessed the usefulness of circulating miRNAs as prognostic tools in HCC [39]. In this study, elevated 
serum levels of miR-221 were associated to shorter overall survival (p-value < 0.05) and identified as an 
independent risk factor for poor prognosis in HCC patients (Hazard ratio = 1.903; 95% confidence 
interval = 1.235–2.981; p-value = 0.018) [39]. 
Table 4. Circulating miRNAs with diagnostic and prognostic applications in HCC 1.  
miRNAs Samples (n) Stage 
(patients) 
Technique Up/ 
Down 2 
Association Ref. 3 
miR-885-5p Serum  
(46 tumours,  
15 liver diseases,  
26 cirrhosis,  
23 HBV,  
24 controls) 
Not 
provided 
qRT-PCR 4 
array 
Up Diagnosis of 
liver pathologies 
[33] 
3-miRNA 
signature: miR-25, 
miR-375, let-7f 
Serum (55 patients, 
50 controls) 
Not 
provided 
Deep 
sequencing + 
qRT-PCR 
Up Diagnosis of 
HBV5-related 
HCC 
[34] 
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Table 4. Cont.  
miRNAs Samples (n) Stage 
(patients) 
Technique Up/ 
Down 2 
Association Ref. 3 
miR-21, miR-122, 
miR-223 
Serum  
(101 tumours,  
48 HBV,  
89 healthy controls) 
Not provided qRT-PCR Up Detection of 
HCC and/or 
HBV (liver 
injury) 
[35] 
miR-16  
(+/− conventional 
serum markers: 
AFP 6, AFP-L3 7, 
DCP 8) 
Serum  
(105 tumours,  
107 chronic liver 
diseases,  
71 controls) 
CLIP 9:  
0-2 (48),  
3-6 (15) 
qRT-PCR Down HCC detection 
in combination 
or in second-
line after testing 
conventional 
serum makers 
[36] 
7-miRNA 
combination:  
miR-21, miR-26a, 
miR-27a, miR-122, 
miR-192, miR-223, 
miR-801 
Plasma  
(400 tumours,  
116 cirrhosis,  
147 HBV,  
134 healthy donors)  
BCLC 10:  
0 (62),  
A (243),  
B (69),  
C (25),  
D (1) 
Microarray +  
qRT-PCR 
Up/ 
Down 
Diagnosis of 
HBV-related 
HCC 
[37] 
miR-122 Serum (72 tumours, 
48 HBV, 34 healthy 
donors) 
TNM 11: I (8), 
II (36),  
III (20), IV (6) 
qRT-PCR Up Detection of 
HBV-related 
HCC 
[38] 
miR-221 Serum (46 tumours, 
20 controls) 
TNM: I (16), 
II (19),  
III-IV (11) 
qRT-PCR Up Shorter overall 
survival 
[39] 
1 Hepatocellular carcinoma; 2 Regarding control samples; 3 References; 4 Quantitative reverse transcription 
polymerase chain reaction; 5 Hepatitis B virus; 6 α-fetoprotein; 7 Lens culinaris agglutinin-reactive α-fetoprotein; 
8 des-γ-carboxyprothrombin; 9 CLIP (Cancer of the Liver Italian Program) staging system; 10 Barcelona Clinic 
Liver Cancer staging system; 11 Tumor, Node, Metastasis staging system. 
Attending to circulating miRNAs in colorectal cancer (Table 5), Chen and colleagues [14] conducted 
for the first time a comprehensive analysis of expression profile of miRNAs in serum by deep 
sequencing. They detected several miRNAs differentially expressed in colorectal cancer compared to 
those found in healthy subjects and lung cancer patients. However, Ng and co-workers provided data 
about the diagnostic performance of miRNAs in plasma of colorectal cancer patients [40]. In this study, 
by analysing 95 miRNAs in plasma form 130 patients and 50 healthy controls, miR-17-3p and miR-92 
were demonstrated to be the best tools to detect colorectal cancer with respective AUCs of 0.717 and 
0.885. Later on, miR-92 (now renamed as miR-92a) and miR-29a, also demonstrated their capacity, 
independently or in combination, to successfully discriminate plasma samples from colorectal cancer 
patients, patients with advanced adenomas and healthy controls [41]. When they were used in 
combination, miR-92a and miR-29a plasma levels showed AUCs of 0.883 and 0.773 to detect 
respectively colorectal cancer and adenomas from healthy subjects. MiR-29a levels in serum were also 
used to detect liver metastasis in colorectal cancer patients with an AUC of 0.803, reaching a 
sensitivity and specificity of 0.75 [42]. In relation to prognosis, the abundance of miR-141 in plasma 
was associated with stage IV colon cancer and it displayed an elevated ability to diagnose this subset 
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of patients. This ability is complemented and enhanced when the miR-141 assay is combined with CEA 
determination. Moreover, high levels of miR-141 in plasma were related to poorer survival in colon cancer 
patients, independently of tumour stage, gender, and age [44]. Likewise, elevated levels of miR-221 in 
plasma were also proposed as an independent prognostic factor for overall survival in colorectal cancer 
patients (hazard ratio: 3.478; 95% confidence interval: 1.038–11.654; p-value = 0.043) [43]. However, the 
AUC (0.606) obtained for miR-221 when was used to detect colorectal cancer from healthy controls, was 
modest in comparison to other circulating miRNA investigated [44]. 
Table 5. Circulating miRNAs with diagnostic and prognostic applications in colorectal cancer.  
1 Tumor, Node, Metastasis staging system; 2 Regarding control samples; 3 References; 4 Quantitative reverse 
transcription polymerase chain reaction; 5 Carcinoembryonic antigen. 
4. Conclusions  
To date, since the discovery of miRNAs as regulatory molecules, a large number of reports have 
elucidated their function, the mechanisms of action, and their expression profile in a wide spectrum of 
organisms, samples and conditions. This huge amount of information has led researchers to understand 
the importance of miRNAs as central players during both the initiation and clinical development of 
many diseases, including cancer. Beyond the possible therapeutic use, these findings have impelled the 
research on miRNAs as clinical biomarkers. In fact, the singular characteristics of miRNAs, such as 
tissue- and disease-specificity, make their use an excellent option to detect physiological and 
pathological alterations. Thus, miRNAs are able to identify, not only the presence or absence of 
tumours, but also can determine the primary organ or tissue affected and the clinical and pathological 
stage. Furthermore, miRNAs can predict risk of progression, relapse, and metastasis, and help to 
evaluate possible clinical scenarios in relation to the therapy response.  
Moreover, because of their presence and stability in different body fluids [45], the primary future 
application of miRNAs is their utilization as non-invasive markers. However, the promising findings 
miRNAs Samples (n) TNM 1 Stage 
(patients) 
Technique Up/ 
Down 2 
Association Ref. 3 
miR-17-3p,  
miR-92 
Plasma (130 CRC 
patients, 50 healthy 
controls) 
I (6), II (35),  
III (39), IV (50) 
qRT-PCR 4 Up Colorectal cancer 
diagnosis 
[40] 
miR-29a,  
miR-92a  
Plasma (100 CRC 
patients,  
37 adenomas,  
59 healthy controls) 
I (27), II (25),  
III (38), IV(10) 
qRT-PCR Up Colorectal cancer 
and adenoma 
diagnosis 
[41] 
miR-29a Serum  
(114 patients) 
Not provided qRT-PCR Up Liver metastasis 
detection 
[42] 
miR-141  
(+CEA 5) 
Plasma (185 CRC 
patients, 76 healthy 
controls) 
I (11), II (63),  
III (49), IV (62) 
qRT-PCR Up Poor survival [43] 
miR-221 Plasma  
(103 patients,  
37 healthy controls) 
I-II (36), III-IV (44) qRT-PCR Up Colorectal cancer 
diagnosis; poor 
overall survival  
[44] 
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performed to date are hampered by the variability in sample sources. In addition to the determination 
of miRNAs in blood, they have been also successfully isolated from clinically relevant samples, such 
as stool [46] and urine [47], and from forensic samples, such as saliva and semen [48]. However, the 
favourite sample type is blood derivative due to the reliable determination of the disease status in these 
samples and the presence of higher amounts of miRNAs. Among blood derivatives, serum is most 
frequently used in biomarker studies, probably to avoid the technical issues related to the presence of 
anticoagulants in plasma. Up to now, no relevant studies have been performed on whole blood, due to 
the possible interference of miRNAs from blood cells. However, the use of whole blood to search for 
miRNA biomarkers could be interesting as, conversely to plasma and serum, handling is not necessary 
prior obtaining the sample. Consequently, this sample type provides a scalable solution for future 
technological implementations for fast and in situ determinations.  
Therefore, due to the obstacles related to heterogeneity of available detection techniques and sample 
sources, there are few clinical trials conducted to evaluate the potential clinical application of miRNA 
biomarkers. However, the mentioned impediments will be undoubtedly overcome and the clinical 
implementation of circulating miRNAs as genuine “microsensors” in cancer will become a reality in 
the near future.  
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